



Published in final edited form as:

*Bone Marrow Transplant.* 2017 February ; 52(2): 173–182. doi:10.1038/bmt.2016.203.

## Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT

Z DeFilipp<sup>1</sup>, RF Duarte<sup>2</sup>, JA Snowden<sup>3</sup>, NS Majhail<sup>4</sup>, DM Greenfield<sup>5</sup>, JL Miranda<sup>6</sup>, M Arat<sup>7</sup>, KS Baker<sup>8</sup>, LJ Burns<sup>9</sup>, CN Duncan<sup>10</sup>, M Gillece<sup>11</sup>, GA Hale<sup>12</sup>, M Hamadani<sup>13</sup>, BK Hamilton<sup>4</sup>, WJ Hogan<sup>14</sup>, JW Hsu<sup>15</sup>, Y Inamoto<sup>16</sup>, RT Kamble<sup>17</sup>, MT LupoStanghellini<sup>18</sup>, AK Malone<sup>19</sup>, P McCarthy<sup>20</sup>, M Mohty<sup>21,22,23</sup>, M Norkin<sup>15</sup>, P Papham<sup>20</sup>, M Ramanathan<sup>24</sup>, JM Richart<sup>25</sup>, N Salooja<sup>26</sup>, HC Schouten<sup>27</sup>, H Schoemans<sup>28</sup>, A Seber<sup>29,30</sup>, A Steinberg<sup>19</sup>, BM Wirk<sup>31</sup>, WA Wood<sup>32</sup>, M Battiwalla<sup>33</sup>, MED Flowers<sup>8</sup>, BN Savani<sup>34</sup>, and BE Shawon<sup>13</sup> on behalf of the CIBMTR Late Effects and Quality of Life Working Committee and the EBMT Complications and Quality of Life Working Party

<sup>1</sup>Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA <sup>2</sup>Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain

<sup>3</sup>Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust and Department of Oncology & Metabolism, University of Sheffield, Sheffield, UK <sup>4</sup>Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH, USA <sup>5</sup>Specialized Cancer Services, Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, UK <sup>6</sup>Department of Medicine, Reina Sofia University Hospital, Maimonides Institute for Biomedical Research at Cordoba (IMIBIC), University of Cordoba, CIBER Fisiopatología Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain <sup>7</sup>Florence Nightingale Sisli Hospital, Hematopoietic Stem Cell Transplantation Unit, Istanbul, Turkey <sup>8</sup>Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA <sup>9</sup>National Marrow Donor Program, University of Minnesota, Minneapolis, MN, USA <sup>10</sup>Pediatric Stem Cell Transplant, Dana-Farber Cancer Institute, Boston, MA, USA <sup>11</sup>Leeds Teaching Hospitals NHS Trust, Leeds, UK <sup>12</sup>All Children's Hospital, John Hopkins Medicine, St. Petersburg, FL, USA <sup>13</sup>Department of Medicine, Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, WI, USA <sup>14</sup>Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA <sup>15</sup>Division of Hematology & Oncology, Department of Medicine, University of Florida, Gainesville, FL, USA <sup>16</sup>Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan <sup>17</sup>Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA <sup>18</sup>Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milano, Italy <sup>19</sup>Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, USA <sup>20</sup>Department of Medicine, Roswell Park Cancer Institute, BMT Program, Buffalo, NY, USA

Corresponding Author: Bronwen Shaw, MD PhD, Department of Medicine, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin 9200 W Wisconsin Ave, Milwaukee, WI 53226, Phone: 414-805-0700, Fax: 414-805-0714, beshaw@mcw.edu.

**Conflict of Interest:** The authors declare no conflict of interest.

<sup>21</sup>University Pierre & Marie Curie, Paris, France <sup>22</sup>Hopital Saint-Antoine, AP-HP, Paris, France  
<sup>23</sup>INSERM UMRs 938, Paris, France <sup>24</sup>Department Hematology, Oncology and Bone Marrow Transplant, UMass Memorial Medical Center, Worcester, MA, USA <sup>25</sup>Division of Hematology and Medical Oncology, Department of Internal Medicine, Saint Louis University, St. Louis, MO, USA  
<sup>26</sup>Hammersmith Hospital, London, UK <sup>27</sup>Maastricht University Medical Center, Maastricht, The Netherlands  
<sup>28</sup>Department of Hematology, University Hospital Leuven and KU Leuven, Leuven, Belgium  
<sup>29</sup>Hospital Samaritano, Sao Paulo, Brazil <sup>30</sup>Associação da Medula Ossea - AMEO, Sao Paulo, Brazil  
<sup>31</sup>Department of Internal Medicine, Stony Brook University Medical Center, Stony Brook, NY, USA  
<sup>32</sup>Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA  
<sup>33</sup>Hematology Branch, National Institutes of Health, Bethesda, MD, USA  
<sup>34</sup>Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

## Abstract

Metabolic syndrome (MetS) is a constellation of cardiovascular risk factors that increases the risk of cardiovascular disease, diabetes mellitus and all cause mortality. Long-term survivors of hematopoietic cell transplantation (HCT) have a substantial risk of developing MetS and cardiovascular disease, with the estimated prevalence of MetS being 31–49% among HCT recipients. Although MetS has not yet been proven to impact cardiovascular risk after HCT, an understanding of the incidence and risk factors for MetS in HCT recipients can provide the foundation to evaluate screening guidelines and develop interventions that may mitigate cardiovascular-related mortality. A working group was established through the Center for International Blood and Marrow Transplant Research and the European Group for Blood and Marrow Transplantation with the goal of reviewing literature and recommend practices appropriate to HCT recipients. Here we deliver consensus recommendations to help clinicians provide screening and preventive care for MetS and cardiovascular disease among HCT recipients. All HCT survivors should be advised of the risks of MetS and encouraged to undergo recommended screening based on their predisposition and ongoing risk factors.

## Introduction

Advances in hematopoietic cell transplantation (HCT) and supportive care have led to substantial improvements in transplant outcomes and an increased number of long-term HCT survivors.<sup>1</sup> Transplant survivors are at considerable risk for developing significant late effects and experience mortality rates higher than the general population.<sup>2,3</sup> One challenge faced in the post-HCT setting is the development of metabolic syndrome (MetS), with reported prevalence rates of 31–49%.<sup>4–8</sup> HCT recipients are predisposed to develop MetS through several mechanisms, including conditioning regimen-mediated damage to the neurohormonal system and vascular endothelium, as well as the immunological and inflammatory effects of allografting (including subsequent GvHD and its therapy).<sup>4</sup> Individuals in the general population with MetS are twice as likely to develop cardiovascular disease than those without MetS.<sup>9</sup> A better understanding of MetS following HCT may prove to be significant, as HCT survivors are known to be at increased risk for

cardiovascular morbidity and mortality. In the Bone Marrow Transplant Survivor Study (BMTSS), the risk of premature cardiovascular-related death following HCT was found to be increased 2.3-fold compared with the general population.<sup>2,3</sup> Similarly, others have reported the risk of cardiovascular hospitalizations and mortality to be increased by 3.6-fold in HCT recipients compared with the general population.<sup>10</sup>

Intensive chemotherapy and radiation have been associated with MetS and contribute to the development of this syndrome post HCT, especially in heavily pre-treated populations.<sup>11,12</sup> MetS has not yet been proven to impact cardiovascular risk after HCT. However, an understanding of the incidence and risk factors for MetS and cardiovascular disease following HCT provides the foundation to evaluate screening guidelines and develop interventions that may mitigate cardiovascular-related mortality. Therefore, a collaboration was established between the Center for International Blood and Marrow Transplant Research (CIBMTR) Late Effects and Quality of Life Working Committee and the European Group for Blood and Marrow Transplantation (EBMT) Complications and Quality of Life Working Party with the goal to review literature, including previously published guidelines for screening and preventive practices for HCT survivors.<sup>13–15</sup> We subsequently provide specific screening and preventive practice recommendations for MetS and cardiovascular disease appropriate to HCT recipients based on published evidence and expert opinion.

## Metabolic Syndrome

MetS is a cluster of interrelated factors that increases the risk of cardiovascular disease, diabetes mellitus (DM) and all cause mortality.<sup>16–18</sup> The International Diabetes Foundation (IDF) estimates that 25% of the world's adult population has MetS.<sup>19</sup> The four core clinical measures are increased body weight/visceral adiposity, elevated lipids, raised blood pressure (BP) and hyperglycemia/insulin resistance (IR).<sup>20</sup> The individual diagnostic criteria of MetS have varied over time according to the different definitions applied. The diagnostic criteria of the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATPIII),<sup>9,21</sup> the IDF, and the American Heart Association (AHA)<sup>17</sup> and the World Health Organization<sup>22</sup> are shown in Table 1. A comparison of various definitions in terms of their predictive value established that the prevalence of MetS was significantly greater when using the criteria of the AHA and IDF compared with the NCEP ATPIII definition.<sup>23</sup> However, the risks of cardiovascular events and death were markedly greater for participants who satisfied any of the criteria for diagnosis of MetS compared with healthy individuals. This supports other reports that found agreement between MetS components and cardiovascular risk factors in the general population.<sup>24,25</sup>

## Abdominal Obesity

Obesity, defined as a body mass index (BMI)  $\geq 30$  kg/m<sup>2</sup>, affects 35% of adults in the United States of America<sup>26</sup> and 10–30% of adults in Europe.<sup>27</sup> Obese persons have a higher risk of developing serious medical conditions, including hypertension (HTN), dyslipidemia, type 2 DM, coronary heart disease (CHD) and ischemic stroke, and have a higher mortality than the non-obese population.<sup>28</sup> However, BMI is an insufficient measure of abdominal obesity. Waist circumference, which emphasizes visceral adipose deposits, is preferentially

used in the evaluation of abdominal obesity when defining MetS (Table 1) as this distribution of fat accumulation independently confers cardiometabolic risk.<sup>29,30</sup> Yet, as studies reporting waist circumference at the time of and following HCT are limited, BMI may act as a possible surrogate.

BMI  $\geq 35$  kg/m<sup>2</sup> (severely obese) 'has been part of' the HCT-specific comorbidity index since 2005, as this was determined to be a risk factor for increased non-relapse mortality.<sup>31–34</sup> While pre-transplant obesity can influence body composition following HCT, changes in waist circumference can be seen independent of pre-existing obesity. Despite what may be a normal BMI, HCT survivors are at an increased risk to develop sarcopenic obesity (increase in percent fat mass, decrease in lean body mass), which can significantly contribute to IR.<sup>35,36</sup> A longitudinal study using dual-X-ray absorptiometry to calculate body fat mass index in 82 patients found the prevalence of a high body fat mass index was greater at 2–3 years following allo-HCT than in healthy controls.<sup>37</sup> Corticosteroids, which remain the first-line treatment of GvHD, contribute to sarcopenic obesity by promoting muscle atrophy and may contribute to obesity in the early post-HCT period.<sup>5,38</sup> Robust data on the changes in abdominal obesity following autologous HCT (auto-HCT) are lacking. One study evaluated metabolic and body composition changes in 32 patients with multiple myeloma who had received three lines of intensive treatment including at least one HCT. At a median duration of 6 years from diagnosis, dual-X-ray absorptiometry identified sarcopenic obesity in 65% of patients.<sup>39</sup> Importantly, the development of sarcopenic obesity following HCT has yet to be independently associated with increased cardiovascular mortality. In the pediatric population, a cross-sectional study evaluating 54 allo-HCT survivors and 894 healthy participants found a deficiency in lean mass (as identified by dual-X-ray absorptiometry) as compared with fat mass in HCT survivors.<sup>40</sup> A prospective, descriptive cross-sectional study evaluating children and adolescents for the development of MetS post HCT found that 73% of individuals with this diagnosis had a characteristic of abdominal obesity (abdominal circumference 475th percentile by age and gender).<sup>5</sup>

### Screening and preventive recommendations

The United States Preventive Services Task Force (USPSTF) and the National Heart, Lung, Blood Institute (NHLBI) recommend screening for obesity in all adults and children 42 years of age, though no recommendation is made regarding appropriate intervals for screening. Current guidelines for HCT recipients do not provide specific screening recommendations for abdominal obesity, though education and counseling regarding regular exercise, healthy weight and dietary counseling are encouraged.<sup>14,15</sup> Given the increase in abdominal obesity that can occur after HCT, clinicians should consider monitoring body composition at each visit, with regular measurement of height, weight and waist circumference (at least yearly). Based on what is known in other populations, we recommend that patients with a BMI  $\geq 30$  kg/m<sup>2</sup>, waist circumference  $>102$  cm ( $>40$  inches) in men or  $>88$  cm ( $>35$  inches) in women or significant increases in either of these measurements should be considered for intensive, multicomponent behavioral interventions. Dual-X-ray absorptiometry may be used to assist evaluation and monitoring of changes in body composition in survivors of HCT.

## Dyslipidemia

Dyslipidemia, defined as elevated levels of total cholesterol, low-density lipoprotein cholesterol or triglycerides, or low levels of high-density lipoprotein (HDL) cholesterol, is an important risk factor for CHD and ischemic stroke.<sup>41,42</sup> The prevalence of dyslipidemia is high in the general population: in 2000, ~ 25% of adults in the United States of America had total cholesterol greater than 240 mg/dL ( 6.2 mmol/L) or were taking lipid-lowering medication.<sup>43</sup> A high prevalence of dyslipidemia has also been reported in European countries.<sup>44,45</sup> Of the various dyslipidemias, low HDL (<40– 50 mg/dL, <1.0–1.3 mmol/L) and hypertriglyceridemia (>150 mg/dL, >1.7 mmol/L) have been incorporated into the diagnostic criteria of MetS (Table 1).

Survivors of allo-HCT are at an increased risk of post-transplant dyslipidemia. In a retrospective cohort study comparing incidence and risk factors for cardiovascular events, allo-HCT recipients had significantly higher risk of new onset dyslipidemia (relative risk (RR): 2.31; 95% confidence interval (CI), 1.15–4.65) compared with auto-HCT recipients.<sup>46</sup> Single-institution studies have estimated the incidence of hypercholesterolemia and/or hypertriglyceridemia following allo-HCT to be 43– 73%.<sup>47,48</sup> The onset of dyslipidemia post HCT can be rapid, with the median interval to the development of hypertriglyceridemia and hypercholesterolemia being 8 and 11 months following allo-HCT, respectively, in one single-center experience.<sup>47</sup> Factors predicting development of post-HCT dyslipidemia include family history of hyperlipidemia, obesity, high-dose TBI, grade II–IV acute GvHD, chronic GvHD and chronic liver disease.<sup>5,8,47–49</sup> In addition, immunosuppressant medications (for example, sirolimus, calcineurin inhibitors and corticosteroids) not only increase lipid levels but also lead to significant drug–drug interactions with 3-hydroxy-3-methylglutaryl–CoA reductase inhibitors (statins) via the cytochrome p450 pathway.<sup>50,51</sup> Data regarding the incidence of dyslipidemia following auto-HCT are limited. In a single-center analysis evaluating late post-HCT cardiovascular complications in 1379 patients, which included both auto- and allo-HCT recipients, 1 year post-HCT dyslipidemia requiring treatment was associated with an increased risk for stroke (hazard ratio = 7.4; 95% CI, 1.2–47).<sup>52</sup> In the pediatric population, the risk of hypercholesterolemia is high in childhood cancer survivors who underwent auto-HCT (hazard ratio = 3.2; CI, 1.7–5.9).<sup>53</sup>

## Screening and preventive recommendations

The USPSTF strongly recommends screening for lipid disorders every 5 years in men 35 years, women 45 years and persons 20 years at increased risk for CHD, whereas the NHLBI recommends screening in children between the ages of 9–11 years or earlier in those with family history. Current guidelines for HCT recipients recommend similar screening practices for dyslipidemia among the general population.<sup>14,15</sup> We recommend standard risk patients (including auto-HCT recipients without personal risk factors) should follow these guidelines. However, early onset of dyslipidemia following allo-HCT is not uncommon, especially in high-risk patients. Thus, we propose early assessment of exposures and risk factors in all HCT patients. For recipients of alloHCT, we suggest an initial lipid profile 3 months after HCT. For high-risk patients with ongoing risk factors (including those on sirolimus, calcineurin inhibitors and corticosteroids), we suggest repeat evaluation every 3–6

months. In recipients without ongoing risk factors, we suggest repeat evaluation according to recommendations for the general population. Non-pharmacologic management of dyslipidemia primarily involves lifestyle modifications such as diet (low saturated fat and low cholesterol), exercise (or other regular physical activities), weight reduction, smoking cessation and limiting alcohol intake. Although not validated among HCT survivors, we recommend use of the Framingham risk score (<http://cvdrisk.nhlbi.nih.gov>) to assess cardiovascular risk and guide therapy decisions.<sup>41</sup> The safety of lipid-lowering agents must be considered in the pediatric population, as the AHA recommends considering drug therapy for high-risk lipid abnormalities in boys > 10 years of age and after onset of menses in girls, preferably after a 6–12 month trial of saturated fat- and cholesterol-restricted dietary management.<sup>54</sup>

## Hypertension

HTN, defined as a systolic BP ≥ 140 mm Hg or diastolic BP ≥ 90 mm Hg, is a worldwide epidemic affecting ~ 25% of adults.<sup>55</sup> Of note, the BP criteria used in most definitions of MetS is systolic BP ≥ 135 mm Hg or diastolic BP ≥ 85 mm Hg (or drug treatment for HTN) (Table 1), which is classified as pre-HTN according to the report from the Eighth Joint National Committee.<sup>56</sup>

An analysis of the BMTSS showed that after adjustment for age, sex, race and BMI, allo-HCT recipients were 2.06 times (95% CI, 1.39–3.04) more likely to report HTN as compared with sibling donors or auto-HCT recipients, who had a similar risk (odds ratio, 0.96; 95% CI, 0.65–1.44).<sup>57</sup> Similarly, a retrospective, single-institution evaluation of 265 long-term transplant survivors reported that allo-HCT recipients have an increased risk of HTN (RR: 2.50; 95% CI, 1.19–5.27) compared with auto-HCT patients.<sup>46</sup> A direct cause and effect relationship of conditioning regimen, acute or chronic GvHD and HTN was not established.<sup>57</sup> Two large retrospective studies did not show a significant difference in the incidence of HTN in allo-HCT recipients with or without GvHD.<sup>57,58</sup> It appears that HTN is related to use of certain GvHD therapies (for example, calcineurin inhibitors, steroids) rather than GvHD-induced pro-inflammatory cytokine response and endothelial damage. Although pediatric patients are less likely than adults to have pre-transplant HTN as well as any risk factors for HTN, an analysis of 1 year survivors of allo-HCT found a similar incidence of post-HCT HTN in adult (68%) and pediatric (73%) HCT survivors.<sup>59</sup> In multivariate analyses, exposure to cyclosporine increased the risk of HTN post HCT (RR: 1.6; 95% CI, 1.1–2.5), but only within the first 2 years, suggesting this may revert once medications are stopped.

## Screening and preventive recommendations

The USPSTF recommends BP assessment every 3–5 years in adults aged 18–39 years with normal BP (<130/85 mm Hg) who do not have other risk factors and annually in adults aged ≥ 40 years and for those who are at increased risk of high BP. In children, the NHLBI recommends BP assessment yearly after the age of 3 years, interpreted for age, sex and height. Current guidelines for HCT recipients recommend at least annual BP assessment in children and BP assessment every other year in adults.<sup>14,15</sup> We recommend BP assessment

for HCT recipients at every clinic visit (at least yearly). The Joint National Committee 8 report recommends initiating pharmacologic treatment for BP of 150/ 90 mm Hg in persons ≥ 60 years of age (to a BP goal of <150/<90 mm Hg) and for BP of 140/ 90 in persons 30–59 years of age (to a BP goal of <140/<90).<sup>56</sup> In the absence of HCT-specific evidence, these goals can be used to guide management of HCT recipients, but other factors, such as end organ compromise (cardiac or renal failure) and therapy with calcineurin inhibitors, also need to be taken into account.

## Insulin Resistance/Diabetes Mellitus

DM, which affects almost 10% of the adult population worldwide, is characterized by hyperglycemia resulting from defects in insulin secretion, insulin action or both. The chronic hyperglycemia of DM is associated with long-term damage, dysfunction and failure of various organs, especially the eyes, kidneys, nerves, heart and blood vessels. The American Diabetes Association defines DM as a fasting plasma glucose ≥ 126 mg/dL ( 7 mmol/L), a hemoglobin A1C (HbA1C) ≥ 6.5%, a 2-h plasma glucose ≥ 200 mg/dL ( 11.1 mmol/L) during an oral glucose tolerance test, or a random glucose ≥ 200 mg/dl ( 11.1 mmol/L) in a patient with classic symptoms or hyperglycemia or hyperglycemic crisis.<sup>60</sup> Impaired fasting glucose (fasting glucose 100–126 mg/dL (5.6– 7 mmol/L)) or DM are used in most definitions of MetS (Table 1). The treatment of DM may reduce the progression of microvascular and cardiovascular disease.<sup>61–64</sup> Although randomized trials have failed to demonstrate an unequivocal benefit, the identification of patients by screening allows for earlier intervention with potential reduction in complications.<sup>65,66</sup>

While hyperglycemia and impaired glucose tolerance are well-recognized complications of cancer and GvHD treatment (corticosteroids), data regarding the long-term risk of DM in HCT survivors are limited.<sup>67</sup> In the BMTSS, both allo-HCT (odds ratio, 3.65; 95% CI, 1.82–7.32) and auto-HCT (odds ratio, 2.03; 95% CI, 0.98–4.21) recipients were more likely to report DM than sibling donors.<sup>57</sup> The incidence of post-HCT DM was 30% among 1 year allo-HCT recipients in both adult and pediatric populations.<sup>59</sup> In this study, exposure to high-dose corticosteroids (cumulative prednisone dose of <0.25 mg/kg/day) increased the likelihood of developing DM (RR: 3.6; 95% CI, 1.7–7.5) and for having persistent DM at 2 years post HCT (RR: 4.1; 95% CI, 1.0–18.2). While data regarding the incidence of IR in survivors of adult HCT are lacking, the incidence of IR for pediatric HCT survivors has been estimated to be 10– 52% in single-center studies.<sup>68–71</sup> These reports suggest an increased risk for IR/DM in survivors of both allo- and auto-HCT compared with patients treated with chemotherapy alone or untreated siblings, even when off immunosuppressive treatments. Preliminary data from a cross-sectional study including 151 HCT survivors (76.8% allo-HCT) and 92 sibling controls found HCT survivors who had received TBI conditioning to be significantly more likely to have IR than their sibling controls, but there was no increased risk of IR for those patients who had a history of acute or chronic GvHD (KS Baker, personal communication). Multiple studies found high-dose TBI as a risk factor for IR and impaired glucose tolerance, in addition to older age and lipodystrophic body type.<sup>70–73</sup> Although data have not demonstrated an increased risk of diabetes to be directly associated with history of GvHD, further study is warranted.

## Screening and preventive recommendations

The most common tests to screen for diabetes are fasting plasma glucose, 2 h plasma glucose during an oral glucose tolerance test and HbA1C. The USPSTF recommends screening for abnormal blood glucose (HbA1C, fasting plasma glucose or oral glucose tolerance test) every 3 years in adults aged 40–70 years who are overweight or obese. The NHLBI recommends screening with a fasting glucose every 2 years after the age of 10 years in overweight children with other risk factors. Current guidelines for HCT recipients recommend screening for type 2 DM every 3 years in adults aged ≥45 years or in those with sustained higher BP (<135/80 mm Hg) and fasting glucose at least every 5 years in pediatric survivors,<sup>14,15</sup> which should be appropriate for standard risk patients. For high-risk patients with ongoing risk factors (including those on systemic corticosteroids), we recommend screening for abnormal blood glucose (HbA1C or fasting plasma glucose) 3 months after HCT with repeat evaluation every 3–6 months. For patients with impaired fasting glucose, we encourage weight reduction and increased physical activity, whereas patients with type 2 DM should implement lifestyle therapy and pharmacotherapy, if necessary, to achieve near-normal HbA1C (<7%).

## Coronary Heart Disease

More people die from cardiovascular disease each year than from any other cause. Cardiovascular disease is caused by disorders of blood vessels and is closely related to atherosclerosis, where endothelial lesions occur up to decades before clinical manifestations.<sup>74,75</sup> Risk factors for arteriosclerosis in the general population are well established and include smoking, arterial HTN, obesity, DM, dyslipidemia, familial history of CHD, physical inactivity, male gender and elevated C-reactive protein.<sup>76</sup>

Several studies have attempted to assess the incidence of cardiovascular disease after HCT, with or without a comparison with a control population. A retrospective multicenter EBMT analysis showed that 3.6% of long-term allo-HCT survivors transplanted between 1990 and 1995 had a cardiovascular event in at least one arterial territory observed.<sup>77</sup> The cumulative incidence of a first cardiovascular event 15 years after HCT was 6% (95% CI, 3–10%). One study reported a cumulative incidence of 7.5% for the first cardiovascular event at 15 years post allo-HCT, as compared with 2.3% post auto-HCT.<sup>46</sup> In multivariate analysis, allo-HCT, in addition to at least 2 of 4 cardiovascular risk factors (HTN, dyslipidemia, DM and obesity) was associated with a higher incidence of cardiovascular events (RR: 12.4;  $P=0.02$ ). In a retrospective cohort study, 2 year HCT survivors experienced an increased incidence of cardiovascular death (adjusted incidence rate difference, 3.6 per 1000 person-years (95% CI, 1.7–5.5) when compared with the general population.<sup>10</sup> In this study, an increased cumulative incidence was also found for ischemic heart disease, cardiomyopathy or heart failure, stroke, vascular diseases, and rhythm disorders and an increased incidence of related conditions that predispose toward more serious cardiovascular disease (HTN, renal disease, dyslipidemia and DM). In another study, HCT recipients had significantly higher rates of cardiomyopathy (4.0% vs 2.6%), stroke (4.8% vs 3.3%), dyslipidemia (33.9% vs 22.3%) and DM (14.3% vs 11.7%) ( $P<0.05$  for all comparisons) than the general population, though lower rates of ischemic heart disease (6.1% vs 8.9%;  $P<0.01$ ).<sup>49</sup> In the



BMTSS, survivors of both allo- and auto-HCT were not more likely to report arterial disease, myocardial infarction or stroke than sibling donors.<sup>57</sup> One series, which included 42.7% allo-HCT recipients, reported an incremental increase in 10-year incidence of cardiovascular disease by number of cardiovascular risk factors (4.7% (no factor), 7.0% (one risk factor), 11.2% ( 2 risk factors),  $P<0.01$ ); the risk was especially high (15.0%) in patients with multiple risk factors and pre-HCT exposure to anthracyclines or chest radiation.<sup>78</sup> In the adult population, it is important to acknowledge that an increasing number of older patients are undergoing allo-HCT with reduced intensity conditioning and that future studies are needed to assess the incidence of cardiovascular complications in this population.

In children with acute lymphoblastic leukemia, high-dose TBI and cranial irradiation correlated with multiple adverse cardiovascular factors including central adiposity, HTN, IR and dyslipidemia.<sup>79,80</sup> Some studies have analyzed the correlation with GvHD and either found a correlation<sup>81</sup> or not<sup>46,57</sup> and if so, more likely with acute than chronic GvHD.<sup>77,78</sup>

### Screening and preventive recommendations

In the general population, a person's 10-year risk for CHD is determined based on age, gender and conventional CHD risk factors such as smoking, HTN and dyslipidemia (Framingham risk score, <http://cvdrisk.nhlbi.nih.gov>).<sup>82</sup> Overall, the benefits of screening with resting or exercise electrocardiography or for non-traditional risk factors, including coronary artery calcification on electron beam computerized tomography, have not been clearly demonstrated to outweigh harms. The USPSTF recommends against screening with electrocardiography in asymptomatic adults with low risk for CHD and concludes that there is insufficient evidence to assess the balance of benefits and harms of screening with resting or exercise electrocardiography in asymptomatic adults at intermediate or high risk for CHD events. Similarly, the USPSTF finds insufficient evidence to assess the balance of benefits and harms of using non-traditional risk factors to screen asymptomatic men and women with no history of CHD to prevent CHD events. Current guidelines for HCT recipients do not provide specific screening recommendations for CHD.<sup>14</sup> Decisions about screening in adults at increased risk should be made on a case-by-case basis and after careful discussion with the patient about the risks and benefits of screening. Although little data are available about specific interventions in the HCT populations, we recommend a similar approach.

### Ischemic Stroke

Stroke is the fourth leading cause of death in the United States of America, whereas globally it is the second most common cause of mortality and the third most common cause of disability.<sup>83,84</sup> Globally, stroke incidence from ischemia is 68 and 32% from hemorrhagic stroke (intracerebral and subarachnoid combined).<sup>85</sup> Pediatric stroke is one of the top ten causes of death in children, occurring at 11 per 100 000 children per year, with acute ischemic stroke accounting for half of all cases.<sup>86–88</sup>

The cumulative incidence of stroke after adult HCT has been reported in single-center series to be 1–5% at a median of 4–10 years following HCT.<sup>10,46,49,79,89</sup> In one study of 3833 HCT survivors of 1 year (71.3% allo-HCT), the prevalence of stroke at a median of 10.8

years since HCT was slightly higher than in a matched general population sample (4.8% vs 3.3%).<sup>49</sup> Reported risk factors for stroke include hyperlipidemia, suboptimal physical activity, HTN treatment before HCT, BMI  $\geq 30$  kg/m<sup>2</sup> at HCT and recurrence of the original disease.<sup>10,49,52</sup> The risk of stroke did not differ statistically between auto- or allo-HCT, gender, age at HCT, TBI dose, smoking history, donor type, stem cell source, fruit or vegetable intake and prior cranial radiation.<sup>10,49,52,57</sup> A history of chronic GvHD was associated with an increased risk of stroke among  $\geq 5$ -year HCT survivors (odds ratio, 2.0; 95% CI, 1.1–3.6) in one study,<sup>49</sup> whereas it was not statistically associated with risk of stroke in the other studies. Although ischemic stroke is an indication for HCT in sickle cell disease, reports indicate that there is no increased risk post HCT in this population. In one report of pediatric sickle cell disease patients, two had transient ischemic attacks after allo-HCT but not stroke.<sup>90</sup> Similarly, another study of pediatric sickle cell disease matched related allo-HCT patients did not report stroke in those with successful engraftment.<sup>91</sup> Adult sickle cell disease may have a higher risk of stroke and allo-HCT studies in the adult population are ongoing.

Although the reported incidence of stroke in HCT survivors is low, it may be under recognized due to under reporting. Central nervous system complications—such as stroke, posterior reversible encephalopathy syndrome and seizures—also occur frequently in the early post-HCT follow up with significant impact on patient survival.<sup>92</sup> Beside the well-known posterior reversible encephalopathy syndrome, calcineurin inhibitors may cause a reversible cerebral vasoconstriction syndrome that can progress to cerebral infarction.<sup>93</sup> Furthermore neurovascular complications— including stroke and transient ischemic attacks —occur commonly upon initial presentation of thrombotic microangiopathies presentation and cryptogenic stroke may develop before the onset of alarming hematologic abnormalities.<sup>94,95</sup>

### Screening and preventive recommendations

The risk of a first stroke can be assessed by a global risk assessment tool such as the AHA/ American College of Cardiology Cardiovascular Risk Calculation online tool for adults (<http://my.americanheart.org/cvriskcalculator>), which has also been endorsed by the American Academy of Neurology.<sup>96</sup> The USPSTF recommends against screening for asymptomatic carotid artery stenosis in the general adult population. Preventive practice includes performing moderate to vigorous aerobic physical activity for at least 40 min 3–4 times a week, statin therapy according to 10 year calculated cardiovascular risk, implementation of a Mediterranean diet, HTN therapy and weight loss in overweight and obese patients. Current guidelines for HCT recipients do not provide specific screening recommendations for stroke.<sup>14</sup> In the absence of HCT-specific evidence, these goals represent appropriate guidelines for HCT recipients.

### Recommendations for Screening and Preventive Practices

Although evidence demonstrating the benefits of screening and preventive practices in HCT survivors is lacking, this review of MetS and cardiovascular disease emphasizes the high incidence of cardiovascular risk factors and the related morbidity and mortality experienced

by HCT recipients. Based on these data, we present published guidelines for the general population and HCT survivors (Tables 2 and 3), as well as our consensus recommendations on the screening and preventive practices (Table 4) for MetS and cardiovascular disease. We also present risk factors to consider when screening for components of MetS in transplant recipients (Table 5). HCT survivors with no identifiable risk factors should be counseled to have a healthy lifestyle and to follow the well-established screening recommendations for the healthy population. However, high-risk patients with ongoing risk factors should be more closely monitored.

Although not addressed formally in this manuscript, endocrine abnormalities, such as male hypogonadism, premature menopause and hypothyroidism, can occur following HCT and may contribute to MetS cardiovascular risk. Health care providers should be aware of these risks and evaluate for these conditions in HCT survivors, especially in the presence of MetS or those with risk factors.

A number of online tools are available to help providers assess risk in patients. In addition to the Framingham risk score (<http://cvdrisk.nhlbi.nih.gov>), the AHA released a mobile application in 2013 (<http://tools.acc.org/ASCVD-Risk-Estimator>) to estimate 10 year and lifetime risks for atherosclerotic cardiovascular disease in healthy subjects considering age, ethnicity, gender, systolic BP, history of smoking and DM, total and HDL cholesterol. However, these calculators were designed for the general population and have limitation by age, ethnicity and/or comorbid conditions. Furthermore, it is important to acknowledge that these tools have not been validated in HCT survivors and thus potentially underestimate risk in this population.

## Conclusion

We provide consensus recommendations for screening and preventive measures for MetS and cardiovascular disease in recipients of HCT. Such effort by the CIBMTR and EBMT Late Effects Working Groups is intended to raise awareness of the cardiovascular risk in HCT survivors and lead to practices that will decrease related mortality. This document does not discuss strategies to achieve these practices (for example, survivorship clinics, rehabilitation or exercise programs) given the differences in health-care environments between different countries, but efforts to facilitate such strategies to be developed at the local or national level are needed.

## References

1. Majhail NS, Tao L, Bredeson C, Davies S, Dehn J, Gajewski JL, et al. Prevalence of hematopoietic cell transplant survivors in the United States. *Biol Blood Marrow Transplant*. 2013; 19:1498–1501. [PubMed: 23906634]
2. Bhatia S, Francisco L, Carter A, Sun CL, Baker KS, Gurney JG, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. *Blood*. 2007; 110:3784–3792. [PubMed: 17671231]
3. Bhatia S, Robison LL, Francisco L, Carter A, Liu Y, Grant M, et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. *Blood*. 2005; 105:4215–4222. [PubMed: 15701723]

4. Majhail NS, Flowers ME, Ness KK, Jagasia M, Carpenter PA, Arora M, et al. High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant.* 2009; 43:49–54. [PubMed: 18724397]
5. Paris C, Yates L, Lama P, Zepeda AJ, Gutierrez D, Palma J. Evaluation of metabolic syndrome after hematopoietic stem cell transplantation in children and adolescents. *Pediatr Blood Cancer.* 2012; 59:306–310. [PubMed: 22302361]
6. Annaloro C, Usardi P, Airaghi L, Giunta V, Forti S, Orsatti A, et al. Prevalence of metabolic syndrome in long-term survivors of hematopoietic stem cell transplantation. *Bone Marrow Transplant.* 2008; 41:797–804. [PubMed: 18195686]
7. McMillen KK, Schmidt EM, Storer BE, Bar M. Metabolic syndrome appears early after hematopoietic cell transplantation. *Metab Syndr Relat Disord.* 2014; 12:367–371. [PubMed: 25006868]
8. Oudin C, Auquier P, Bertrand Y, Contet A, Kanold J, Sirvent N, et al. Metabolic syndrome in adults who received hematopoietic stem cell transplantation for acute childhood leukemia: an LEA study. *Bone Marrow Transplant.* 2015; 50:1438–1444. [PubMed: 26191949]
9. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation.* 2005; 112:2735–2752. [PubMed: 16157765]
10. Chow EJ, Mueller BA, Baker KS, Cushing-Haugen KL, Flowers ME, Martin PJ, et al. Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation. *Ann Intern Med.* 2011; 155:21–32. [PubMed: 21727290]
11. Oudin C, Simeoni MC, Sirvent N, Contet A, Begu-Le Coroller A, Bordigoni P, et al. Prevalence and risk factors of the metabolic syndrome in adult survivors of childhood leukemia. *Blood.* 2011; 117:4442–4448. [PubMed: 21278355]
12. Gurney JG, Ness KK, Sibley SD, O'Leary M, Dengel DR, Lee JM, et al. Metabolic syndrome and growth hormone deficiency in adult survivors of childhood acute lymphoblastic leukemia. *Cancer.* 2006; 107:1303–1312. [PubMed: 16894525]
13. Rizzo JD, Wingard JR, Tichelli A, Lee SJ, Van Lint MT, Burns LJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. *Biol Blood Marrow Transplant.* 2006; 12:138–151. [PubMed: 16443512]
14. Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. *Biol Blood Marrow Transplant.* 2012; 18:348–371. [PubMed: 22178693]
15. Pulsipher MA, Skinner R, McDonald GB, Hingorani S, Armenian SH, Cooke KR, et al. National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: the need for pediatric-specific long-term follow-up guidelines. *Biol Blood Marrow Transplant.* 2012; 18:334–347. [PubMed: 22248713]
16. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. *Diabetes Care.* 2001; 24:683–689. [PubMed: 11315831]
17. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation.* 2009; 120:1640–1645. [PubMed: 19805654]
18. Shin JA, Lee JH, Lim SY, Ha HS, Kwon HS, Park YM, et al. Metabolic syndrome as a predictor of type 2 diabetes, and its clinical interpretations and usefulness. *J Diabetes Investig.* 2013; 4:334–343.
19. International Diabetes Federation: the IDF consensus worldwide definition of the metabolic syndrome. Available at: <http://www.idf.org/metabolic-syndrome>

20. Kaur J. A comprehensive review on metabolic syndrome. *Cardiol Res Pract.* 2014; 2014:943162. [PubMed: 24711954]
21. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA.* 2001; 285:2486–2497. [PubMed: 11368702]
22. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med.* 1998; 15:539–553. [PubMed: 9686693]
23. Mancia G, Bombelli M, Facchetti R, Casati A, Ronchi I, Quarti-Trevano F, et al. Impact of different definitions of the metabolic syndrome on the prevalence of organ damage, cardiometabolic risk and cardiovascular events. *J Hypertens.* 2010; 28:999–1006. [PubMed: 20308922]
24. Lin CC, Liu CS, Li CI, Lin WY, Lai MM, Lin T, et al. The relation of metabolic syndrome according to five definitions to cardiovascular risk factors--a population-based study. *BMC Public Health.* 2009; 9:484. [PubMed: 20028565]
25. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome--a new worldwide definition. *Lancet.* 2005; 366:1059–1062. [PubMed: 16182882]
26. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. *JAMA.* 2014; 311:806–814. [PubMed: 24570244]
27. World Health Organization Regional Office for Europe. Data and Statistics. Available at: <http://www.euro.who.int/en/health-topics/noncommunicable-diseases/obesity/data-and-statistics>
28. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. *Circulation.* 2014; 129:S102–S138. [PubMed: 24222017]
29. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. *Nature.* 2006; 444:881–887. [PubMed: 17167477]
30. Amato MC, Guarnotta V, Giordano C. Body composition assessment for the definition of cardiometabolic risk. *J Endocrinol Invest.* 2013; 36:537–543. [PubMed: 23612318]
31. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. *Blood.* 2005; 106:2912–2919. [PubMed: 15994282]
32. Aplenc R, Zhang MJ, Sung L, Zhu X, Ho VT, Cooke K, et al. Effect of body mass in children with hematologic malignancies undergoing allogeneic bone marrow transplantation. *Blood.* 2014; 123:3504–3511. [PubMed: 24711663]
33. Fuji S, Kim SW, Yoshimura Ki, Akiyama H, Okamoto Si, Sao H, et al. Possible association between obesity and posttransplantation complications including infectious diseases and acute graft-versus-host disease. *Biol Blood Marrow Transplant.* 2009; 15:73–82. [PubMed: 19135945]
34. Fuji S, Takano K, Mori T, Eto T, Taniguchi S, Ohashi K, et al. Impact of pretransplant body mass index on the clinical outcome after allogeneic hematopoietic SCT. *Bone Marrow Transplant.* 2014; 49:1505–1512. [PubMed: 25111511]
35. Baker KS, Chow E, Steinberger J. Metabolic syndrome and cardiovascular risk in survivors after hematopoietic cell transplantation. *Bone Marrow Transplant.* 2012; 47:619–625. [PubMed: 21643022]
36. Narici MV, Maffulli N. Sarcopenia: characteristics, mechanisms and functional significance. *Br Med Bull.* 2010; 95:139–159. [PubMed: 20200012]
37. Kyle UG, Chalandon Y, Miralbell R, Karsgaard VL, Hans D, Trombetti A, et al. Longitudinal follow-up of body composition in hematopoietic stem cell transplant patients. *Bone Marrow Transplant.* 2005; 35:1171–1177. [PubMed: 15880127]
38. Li C, Liu P, Liu L, Zhang X, Yang P, Sheng H, et al. Metabolic syndrome in hematologic malignancies survivors: a meta-analysis. *Med Oncol.* 2015; 32:422. [PubMed: 25471791]
39. Greenfield DM, Boland E, Ezaydi Y, Ross RJ, Ahmedzai SH, Snowden JA. Endocrine, metabolic, nutritional and body composition abnormalities are common in advanced intensively-treated

- (transplanted) multiple myeloma. *Bone Marrow Transplant*. 2014; 49:907–912. [PubMed: 24710566]
40. Mostoufi-Moab S, Ginsberg JP, Bunin N, Zemel BS, Shults J, Thayu M, et al. Body composition abnormalities in long-term survivors of pediatric hematopoietic stem cell transplantation. *J Pediatr*. 2012; 160:122–128. [PubMed: 21839468]
  41. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation*. 2002; 106:3143–3421. [PubMed: 12485966]
  42. Thompson WG, Gau GT. Hypertriglyceridemia and its pharmacologic treatment among US adults--invited commentary. *Arch Intern Med*. 2009; 169:578–579. [PubMed: 19307520]
  43. Fodor G. Primary prevention of CVD: treating dyslipidaemia. *BMJ Clin Evid*. 2008; 2008
  44. Scheidt-Nave C, Du Y, Knopf H, Schienkiewitz A, Ziese T, Nowossadeck E, et al. Prevalence of dyslipidemia among adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS 1). *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz*. 2013; 56:661–667.
  45. Gonzalez-Juanatey JR, Millan J, Alegria E, Guijarro C, Lozano JV, Vitale GC. Prevalence and characteristics of lipid abnormalities in patients treated with statins in primary and secondary prevention in Spain. *DYSIS-Spain Study*. *Rev Esp Cardiol*. 2011; 64:286–294. [PubMed: 21411216]
  46. Tichelli A, Bucher C, Rovo A, Stussi G, Stern M, Paulussen M, et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. *Blood*. 2007; 110:3463–3471. [PubMed: 17664354]
  47. Kagoya Y, Seo S, Nannya Y, Kurokawa M. Hyperlipidemia after allogeneic stem cell transplantation: prevalence, risk factors, and impact on prognosis. *Clin Transplant*. 2012; 26:E168–E175. [PubMed: 22507357]
  48. Blaser BW, Kim HT, Alyea EP 3rd, Ho VT, Cutler C, Armand P, et al. Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant*. 2012; 18:575–583. [PubMed: 21839706]
  49. Chow EJ, Baker KS, Lee SJ, Flowers ME, Cushing-Haugen KL, Inamoto Y, et al. Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation. *J Clin Oncol*. 2014; 32:191–198.
  50. Griffith ML, Savani BN, Boord JB. Dyslipidemia after allogeneic hematopoietic stem cell transplantation: evaluation and management. *Blood*. 2010; 116:1197–1204. [PubMed: 20439623]
  51. Marini BL, Choi SW, Byersdorfer CA, Cronin S, Frame DG. Treatment of dyslipidemia in allogeneic hematopoietic stem cell transplant patients. *Biol Blood Marrow Transplant*. 2015; 21:809–820. [PubMed: 25459644]
  52. Chow EJ, Wong K, Lee SJ, Cushing-Haugen KL, Flowers ME, Friedman DL, et al. Late cardiovascular complications after hematopoietic cell transplantation. *Biol Blood Marrow Transplant*. 2014; 20:794–800. [PubMed: 24565992]
  53. Felicetti F, D'Ascenzo F, Moretti C, Corrias A, Omede P, Marra WG, et al. Prevalence of cardiovascular risk factors in long-term survivors of childhood cancer: 16 years follow up from a prospective registry. *Eur J Prev Cardiol*. 2015; 22:762–770. [PubMed: 24691151]
  54. McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. *Circulation*. 2007; 115:1948–1967. [PubMed: 17377073]
  55. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. *Lancet*. 2005; 365:217–223. [PubMed: 15652604]
  56. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the

- panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014; 311:507–520. [PubMed: 24352797]
57. Baker KS, Ness KK, Steinberger J, Carter A, Francisco L, Burns LJ, et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. *Blood*. 2007; 109:1765–1772. [PubMed: 17047152]
  58. Pophali PA, Klotz JK, Ito S, Jain NA, Koklanaris E, Le RQ, et al. Male survivors of allogeneic hematopoietic stem cell transplantation have a long term persisting risk of cardiovascular events. *Exp Hematol*. 2014; 42:83–89. [PubMed: 24141092]
  59. Majhail NS, Challa TR, Mulrooney DA, Baker KS, Burns LJ. Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation. *Biol Blood Marrow Transplant*. 2009; 15:1100–1107. [PubMed: 19660723]
  60. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care*. 2010; 33:S62–S69. [PubMed: 20042775]
  61. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. *N Engl J Med*. 1993; 329:977–986. [PubMed: 8366922]
  62. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet*. 1998; 352:837–853. [PubMed: 9742976]
  63. Schellenberg ES, Dryden DM, Vandermeer B, Ha C, Korownyk C. Lifestyle interventions for patients with and at risk for type 2 diabetes: a systematic review and meta-analysis. *Ann Intern Med*. 2013; 159:543–551. [PubMed: 24126648]
  64. Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE, et al. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. *Lancet*. 2012; 379:2243–2251. [PubMed: 22683134]
  65. Selph S, Dana T, Blazina I, Bougatsos C, Patel H, Chou R. Screening for type 2 diabetes mellitus: a systematic review for the U.S. Preventive Services Task Force. *Ann Intern Med*. 2015; 162:765–776. [PubMed: 25867111]
  66. Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, Sargeant LA, Williams KM, Prevost AT, et al. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. *Lancet*. 2012; 380:1741–1748. [PubMed: 23040422]
  67. Griffith ML, Jagasia M, Jagasia SM. Diabetes mellitus after hematopoietic stem cell transplantation. *Endocr Pract*. 2010; 16:699–706. [PubMed: 20439241]
  68. Taskinen M, Saarinen-Pihkala UM, Hovi L, Lipsanen-Nyman M. Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood. *Lancet*. 2000; 356:993–997. [PubMed: 11041401]
  69. Bizzarri C, Pinto RM, Ciccone S, Brescia LP, Locatelli F, Cappa M. Early and progressive insulin resistance in young, non-obese cancer survivors treated with hematopoietic stem cell transplantation. *Pediatr Blood Cancer*. 2015; 62:1650–1655. [PubMed: 26017459]
  70. Wei C, Thyagarajan MS, Hunt LP, Shield JP, Stevens MC, Crowne EC. Reduced insulin sensitivity in childhood survivors of haematopoietic stem cell transplantation is associated with lipodystrophic and sarcopenic phenotypes. *Pediatr Blood Cancer*. 2015; 62:1992–1999. [PubMed: 25989749]
  71. Mostoufi-Moab S, Magland J, Isaacoff EJ, Sun W, Rajapakse CS, Zemel B, et al. Adverse fat depots and marrow adiposity are associated with skeletal deficits and insulin resistance in long-term survivors of pediatric hematopoietic stem cell transplantation. *J Bone Miner Res*. 2015; 30:1657–1666. [PubMed: 25801428]
  72. Hirabayashi K, Nakazawa Y, Matsuura H, Hara Y, Kurata T, Hirabayashi K, et al. Risk factors for diabetes mellitus and impaired glucose tolerance following allogeneic hematopoietic stem cell transplantation in pediatric patients with hematological malignancies. *Int J Hematol*. 2014; 99:477–486. [PubMed: 24557711]
  73. Chemaitilly W, Boulad F, Oeffinger KC, Sklar CA. Disorders of glucose homeostasis in young adults treated with total body irradiation during childhood: a pilot study. *Bone Marrow Transplant*. 2009; 44:339–343. [PubMed: 19308039]

74. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med*. 2005; 352:1685–1695. [PubMed: 15843671]
75. Stoll G, Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. *Stroke*. 2006; 37:1923–1932. [PubMed: 16741184]
76. Lloyd-Jones DM, Leip EP, Larson MG, D'Agostino RB, Beiser A, Wilson PW, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. *Circulation*. 2006; 113:791–798. [PubMed: 16461820]
77. Tichelli A, Passweg J, Wojcik D, Rovo A, Harousseau JL, Masszi T, et al. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. *Haematologica*. 2008; 93:1203–1210. [PubMed: 18556401]
78. Armenian SH, Sun CL, Vase T, Ness KK, Blum E, Francisco L, et al. Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease. *Blood*. 2012; 120:4505–4512. [PubMed: 23034279]
79. Chow EJ, Simmons JH, Roth CL, Baker KS, Hoffmeister PA, Sanders JE, et al. Increased cardiometabolic traits in pediatric survivors of acute lymphoblastic leukemia treated with total body irradiation. *Biol Blood Marrow Transplant*. 2010; 16:1674–1681. [PubMed: 20685399]
80. Lorini R, Cortona L, Scaramuzza A, De Stefano P, Locatelli F, Bonetti F, et al. Hyperinsulinemia in children and adolescents after bone marrow transplantation. *Bone Marrow Transplant*. 1995; 15:873–877. [PubMed: 7581084]
81. Rovó A, Daikeler T, Halter J, Heim D, Tsakiris DA, Stern M, et al. Late altered organ function in very long-term survivors after allogeneic hematopoietic stem cell transplantation: a paired comparison with their HLA-identical sibling donor. *Haematologica*. 2010; 96:150–155. [PubMed: 20851864]
82. Heidenreich PA, Trogon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. *Circulation*. 2011; 123:933–944. [PubMed: 21262990]
83. Heron M. Deaths: leading causes for 2007. *Natl Vital Stat Rep*. 2011; 59:1–95.
84. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet*. 2012; 380:2095–2128. [PubMed: 23245604]
85. Krishnamurthi RV, Feigin VL, Forouzanfar MH, Mensah GA, Connor M, Bennett DA, et al. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. *Lancet Glob Health*. 2013; 1:e259–e281. [PubMed: 25104492]
86. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation*. 2009; 119:480–486. [PubMed: 19171871]
87. Roach ES, Golomb MR, Adams R, Biller J, Daniels S, Deveber G, et al. Management of stroke in infants and children: a scientific statement from a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young. *Stroke*. 2008; 39:2644–2691. [PubMed: 18635845]
88. Riela AR, Roach ES. Etiology of stroke in children. *J Child Neurol*. 1993; 8:201–220. [PubMed: 8409261]
89. Sun CL, Francisco L, Kawashima T, Leisenring W, Robison LL, Baker KS, et al. Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. *Blood*. 2010; 116:3129–3139. [PubMed: 20656930]
90. Bodas P, Rotz S. Cerebral vascular abnormalities in pediatric patients with sickle cell disease after hematopoietic cell transplant. *J Pediatr Hematol Oncol*. 2014; 36:190–193. [PubMed: 24327127]
91. Walters MC, Hardy K, Edwards S, Adamkiewicz T, Barkovich J, Bernaudin F, et al. Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. *Biol Blood Marrow Transplant*. 2010; 16:263–272. [PubMed: 19822218]



92. Bhatt VR, Balasetti V, Jasem JA, Giri S, Armitage JO, Loberiza FR Jr, et al. Central nervous system complications and outcomes after allogeneic hematopoietic stem cell transplantation. *Clin Lymphoma Myeloma Leuk*. 2015; 15:606–611. [PubMed: 26184063]
93. Imataki O, Uemura M, Shintani T, Matsumoto K. Reversible cerebral vasoconstriction syndrome resulted in cerebral infarction after allogeneic stem cell transplantation: a case report. *Ann Hematol*. 2014; 93:895–896. [PubMed: 24061786]
94. Rojas JC, Banerjee C, Siddiqui F, Nourbakhsh B, Powell CM. Pearls and oysters: acute ischemic stroke caused by atypical thrombotic thrombocytopenic purpura. *Neurology*. 2013; 80:e235–e238. [PubMed: 23713092]
95. Haghikia A, Heeren M, Bockmeyer C, Haubitz B, Gwinner W. Progressive multifocal cerebral infarction in a young kidney transplant recipient due to thrombotic microangiopathy. *BMC Nephrol*. 2014; 15:59. [PubMed: 24708483]
96. Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Bravata DM, Chaturvedi S, et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2014; 45:3754–3832. [PubMed: 25355838]

**Table 1**  
**Definitions of metabolic syndrome according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATPIII), the International Diabetes Federation (IDF), the American Heart Association (AHA), and the World Health Organization (WHO)**

	NCEP ATPIII [21]	IDF [26]	AHA [9]	WHO [23]
<b>Definition</b>	3 risk factors	Increased waist circumference plus 2 risk factors	3 risk factors	DM/IFG or IGT or IR plus 2 risk factors
<b>Risk Factor</b>				
Abdominal Obesity	Waist circumference: >102 cm (>40 in) in men; >88 cm (>35 in) in women	Waist circumference: dependent on ethnicity	Waist circumference: >102 cm (>40 in) in men; >88 cm (>35 in) in women	Waist circumference: dependent on ethnicity
Triglycerides	150 mg/dL ( 1.7 mmol/L) or drug treatment for elevated levels	150 mg/dL ( 1.7 mmol/L) or drug treatment for elevated levels	150 mg/dL ( 1.7 mmol/L) or drug treatment for elevated levels	150 mg/dL ( 1.7 mmol/L)
HDL cholesterol				
Men	<40 mg/dL (<1.0 mmol/L) or drug treatment for reduced levels	<40 mg/dL(<1.0 mmol/L) or drug treatment for reduced levels	<40 mg/dL(<1.0 mmol/L) or drug treatment for reduced levels	<35 mg/dL (0.9 mmol/L)
Women	<50 mg/dL (<1.3 mmol/L) or drug treatment for reduced levels	<50 mg/dL (<1.3 mmol/L) or drug treatment for reduced levels	<50 mg/dL(<1.3 mmol/L) or drug treatment for reduced levels	<39 mg/dL (1.0 mmol/L)
Blood Pressure	130/ 85 mmHg or drug treatment for HTN	130/ 85 mmHg or drug treatment for HTN	130/ 85 mmHg or drug treatment for HTN	140/ 90 mmHg
Fasting Glucose	110 mg/dL ( 6.11 mmol/L) or drug treatment for DM	100 mg/dL ( 5.6 mmol/L) or drug treatment for DM	100 mg/dL ( 5.6 mmol/L) or drug treatment for DM	IGT, IFG, or type 2 DM
Microalbuminuria				>30 mg albumin/g creatinine

DM: diabetes mellitus

HDL: high-density lipoprotein cholesterol

HTN: hypertension

IGT: impaired glucose tolerance (2-hour postprandial glucose 140-199 mg/dL (7.8-11.1 mmol/L))

IFG: impaired fasting glucose (fasting glucose 100-126 mg/dL (5.6-7 mmol/L))

IR: insulin resistance

**Table 2**  
**Screening guidelines for metabolic syndrome and cardiovascular risk factors for adult and pediatric patients amongst the general population and HCT survivors**

	<b>General adult population</b> ( <a href="http://www.uspreventiveservicestaskforce.org/">http://www.uspreventiveservicestaskforce.org/</a> )	<b>Adult long-term HCT survivors</b> (Majhail, BBMT, 2012)	<b>General pediatric population</b> ( <a href="http://www.nhlbi.nih.gov">http://www.nhlbi.nih.gov</a> )	<b>Pediatric long-term HCT survivors</b> (Pulsipher, BBMT, 2012)	<b>Our recommendations</b> (CIBMTR/EBMT MeaS collaboration)
Weight, Height, BMI	Weight, height, and BMI assessment in all adults (no specific recommendation for screening interval)	No specific recommendations	Weight, height, and BMI assessment after 2 years of age (no specified screening interval)	Weight, height, and BMI assessment yearly	Weight, height, and BMI assessment at every clinic visit (at least yearly) Waist circumference measurement yearly Consider DXA to assess sarcopenia
Dyslipidemia	Lipid profile assessment every 5 years in males aged 35 years and females aged 45 years. For persons with increased risk for coronary heart disease, assessments should begin at age 20. The interval for screening should be shorter for people who have lipid levels close to those warranting therapy, and longer intervals for those not at increased risk who have had repeatedly normal lipid levels.	Lipid profile assessment every 5 years in males aged 35 years and females aged 45 years. Screening should start at age 20 for anyone at increased risk (smokers, DM, HTN, BMI 30 kg/m <sup>2</sup> , family history of heart disease before age 50 for male relatives or before age 60 for female relatives).	Lipid panel between 9-11 years of age or earlier if family history	Lipid profile at least every 5 years; if abnormal, screen annually	For all allo-HCT recipients, initial lipid profile 3 months after HCT. For high-risk patients with ongoing risk factors (including those on sirolimus, calcineurin inhibitors, corticosteroids), repeat evaluation every 3-6 months. For standard-risk patients, lipid profile assessment every 5 years in males aged 35 years and females aged 45 years. The interval for screening should be shorter for people who have lipid levels close to those warranting therapy.
Blood Pressure	Blood pressure assessment every 3 to 5 years in adults aged 18 to 39 years with normal blood pressure (<130/85 mm Hg) who do not have other risk factors Blood pressure assessment annually in adults aged 40 years and for those who are at increased risk for high blood pressure (blood pressure 130 to 139/85 to 89 mm Hg, those who are overweight or obese, and African Americans)	Blood pressure assessment at least every 2 years	Blood pressure assessment yearly after the age of 3 years, interpreted for age/sex/height	Blood pressure assessment at each visit and at least annually	Blood pressure assessment at every clinic visit (at least yearly)

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Hyperglycemia	<p><b>General adult population</b> (<a href="http://www.uspreventiveservicestaskforce.org/">http://www.uspreventiveservicestaskforce.org/</a>)</p> <p>Screening for abnormal blood glucose (HbA1C, fasting plasma glucose or oral glucose tolerance test) every 3 years in adults aged 40-70 years who are overweight or obese.</p>	<p><b>Adult long-term HCT survivors</b> (Majhail, BBMT. 2012)</p> <p>Screening for type 2 DM every 3 years in adults aged &gt; 45 years or in those with sustained higher blood pressure (&gt;135/80 mm Hg)</p>	<p><b>General pediatric population</b> (<a href="http://www.nhlbi.nih.gov">http://www.nhlbi.nih.gov</a>)</p> <p>Fasting glucose every 2 years after the age of 10 years in overweight children with other risk factors</p>	<p><b>Pediatric long-term HCT survivors</b> (Pulsipher, BBMT. 2012)</p> <p>Fasting glucose at least every 5 years; if abnormal, screen annually</p>	<p><b>Our recommendations</b> (CIBMTR/EBMT MeaS collaboration)</p> <p>For high-risk patients with ongoing risk factors (including those on systemic corticosteroids), screen for abnormal blood glucose (HbA1C or fasting plasma glucose) 3 months after HCT with repeat evaluation every 3-6 months. Consider oral glucose tolerance test to evaluate abnormal screening results. For standard-risk adult patients, screening for abnormal blood glucose every 3 years in adults aged &gt; 45 years or in those with sustained higher blood pressure (&gt;135/80 mm Hg) For standard-risk pediatric patients, fasting glucose at least every 5 years; if abnormal, screen annually</p>
---------------	---	---	--	---	---

Abbreviations: BMI, body mass index; CIBMTR, Center for International Blood and Marrow Transplant Research; DM, diabetes mellitus; DXA, dual X-ray absorptiometry; EBMT, European Group for Blood and Marrow Transplantation; HbA1C, hemoglobin A1C; HCT, hematopoietic cell transplantation; HTN, hypertension;

**Table 3**  
**Preventive practice recommendations for metabolic syndrome and cardiovascular risk factors for adult and pediatric patients amongst the general population and HCT survivors**

	<b>General adult population (Grundy. Circulation. 2005)</b>	<b>Adult long-term HCT survivors (Majhail. BBMT. 2012)</b>	<b>General pediatric population (<a href="http://www.nhlbi.nih.gov">http://www.nhlbi.nih.gov</a>)</b>	<b><i>Our recommendations (CIBMTR/EBMT MetS collaboration)</i></b>
Weight control	Recommend behavioral changes to reduce caloric intake and increase physical activity	Recommend education and counseling on “heart” healthy lifestyle (regular exercise, healthy weight, no smoking, dietary counseling)	Combined weight loss programs that include behavior change counseling, negative energy balance through diet, and increased physical activity	Provide advice regarding intensive, multicomponent behavioral interventions focused on achieving and maintaining healthy weight by reducing caloric intake and increasing physical activity
Dyslipidemia control	Non-pharmacologic treatments include weight reduction, increased physical activity, and antiatherogenic diet Lifestyle modifications and lipid lowering therapies to achieve risk-adapted target for LDL is primary goal, even in MetS. Once LDL is at target, further lipid lowering therapy can be added to achieve targets for HDL and TG. If TG>500 mg/dL (5.65 mmol/L), initiate fibrate or nicotinic acid	Recommend education and counseling on “heart” healthy lifestyle (regular exercise, healthy weight, no smoking, dietary counseling) Treatment goals are based on overall risk of heart disease (eg, >10% chance of coronary heart disease in 10 years). Overall risk assessment will include the following risk factors: age, sex, diabetes, clinical atherosclerotic disease, hypertension, family history, low HDL (<40 mg/dL or 1.0 mmol/L), and smoking.	Non-pharmacologic interventions: CHILD-1 diet, activity education, and weight management If LDL goals not achieved after 6 months on non-pharmacologic intervention, consider statin therapy if age >10 years to achieve tier I treatment goals for LDL	Lifestyle modifications and lipid lowering therapies to achieve risk-adapted target for LDL is primary goal The decision to initiate lipid lowering therapy should include assessment of overall risk of heart disease. ( <a href="http://cvdrisk.nhlbi.nih.gov">http://cvdrisk.nhlbi.nih.gov</a> ) If TG>500 mg/dL (5.65 mmol/L), initiate fibrate or nicotinic acid
Blood pressure control	For BP >120/80 mm Hg: Initiate or maintain lifestyle modifications For BP >140/90 mm Hg (or >130/80 mm Hg for individuals with chronic kidney disease or diabetes): As tolerated, add BP medication as needed to achieve goal BP	Non-pharmacologic treatments may also be tried for mild hypertension and include moderate dietary sodium restriction, weight reduction in the obese, avoidance of excess alcohol intake, and regular aerobic exercise. Treatment is indicated for readings >140/90 in adults on two separate visits at least 1 week apart, unless hypertension is mild or can be attributed to a temporary condition or medication (eg, cyclosporine).	Non-pharmacologic interventions: CHILD-1 diet, activity education, and weight management Up-front initiation of anti-HTN therapy for Stage II HTN; initiation of anti-HTN therapy for Stage I HTN if no response to 6 months of non-pharmacologic intervention	Non-pharmacologic treatments may also be tried for mild hypertension and include moderate dietary sodium restriction, weight reduction in the obese, avoidance of excess alcohol intake, and regular aerobic exercise. Treatment is indicated for readings >140/90 in adults on two separate visits at least 1 week apart, unless hypertension is mild or can be attributed to a temporary condition or medication (eg, cyclosporine).

	<b>General adult population (Grundy, Circulation. 2005)</b>	<b>Adult long-term HCT survivors (Majhail. BBMT. 2012)</b>	<b>General pediatric population (<a href="http://www.nhlbi.nih.gov">http://www.nhlbi.nih.gov</a>)</b>	<b>Our recommendations (CIBMTR/EBMT MetS collaboration)</b>
Glycemic control	For IFG, encourage weight reduction and increased physical activity. For type 2 DM, lifestyle therapy, and pharmacotherapy, if necessary, should be used to achieve near-normal HbA1C (<7%).	Recommend education and counseling on “heart” healthy lifestyle (regular exercise, healthy weight, no smoking, dietary counseling)	Non-pharmacologic interventions: CHILD-1 diet, activity education, and weight management. Consultation with an endocrinologist as needed to maintain optimal plasma glucose and HbA1c for age.	For IFG, encourage weight reduction and increased physical activity. For type 2 DM, lifestyle therapy, and pharmacotherapy, if necessary, should be used to achieve near-normal HbA1C (<7%).

\* NCI/NHLBI Pediatric BMT Consortium publication (Pulsipher. BBMT. 2012) does not provide preventive practice recommendations

Abbreviations: BP, blood pressure; CIBMTR, Center for International Blood and Marrow Transplant Research; CHILD-1, Cardiovascular Health Integrated Lifestyle Diet; DM, diabetes mellitus; EBMT, European Group for Blood and Marrow Transplantation; HbA1C, hemoglobin A1C; HCT, hematopoietic cell transplantation; HDL, high-density lipoprotein cholesterol; HTN, hypertension; IFG, impaired fasting glucose; LDL, low-density lipoprotein; TG, triglycerides

**Table 4**  
**CIBMTR/EBMT screening guidelines and preventive practice recommendations for metabolic syndrome and cardiovascular risk factors for adult and pediatric patients amongst the general population and HCT survivors**

	Screening guidelines	Preventive practice
Weight, Height, BMI	Weight, height, and BMI assessment at every clinic visit (at least yearly) Waist circumference measurement yearly Consider DXA to assess sarcopenia	Provide advice regarding intensive, multicomponent behavioral interventions focused on achieving and maintaining healthy weight by reducing caloric intake and increasing physical activity
Dyslipidemia	For all allo-HCT recipients, initial lipid profile 3 months after HCT. For high-risk patients with ongoing risk factors (including those on sirolimus, calcineurin inhibitors, corticosteroids), repeat evaluation every 3-6 months. For standard-risk patients, lipid profile assessment every 5 years in males aged 35 years and females aged 45 years. The interval for screening should be shorter for people who have lipid levels close to those warranting therapy.	Lifestyle modifications and lipid lowering therapies to achieve relative reductions in LDL is the primary goal. In adults, the decision to initiate lipid lowering therapy should include assessment of overall risk of heart disease ( <a href="http://cvdrisk.nhlbi.nih.gov">http://cvdrisk.nhlbi.nih.gov</a> ). If TG>500 mg/dL (5.65 mmol/L), initiate fibrates or nicotinic acid
Blood Pressure	Blood pressure assessment at every clinic visit (at least yearly)	Non-pharmacologic treatments may also be tried for mild hypertension and include moderate dietary sodium restriction, weight reduction in the obese, avoidance of excess alcohol intake, and regular aerobic exercise. Treatment is indicated for readings >140/90 in adults on two separate visits at least 1 week apart, unless hypertension is mild or can be attributed to a temporary condition or medication (eg, cyclosporine).
Hyperglycemia	For high-risk patients with ongoing risk factors (including those on systemic corticosteroids), screen for abnormal blood glucose (HbA1C or fasting plasma glucose) 3 months after HCT with repeat evaluation every 3-6 months. For standard-risk adult patients, screening for abnormal blood glucose every 3 years in adults aged 45 years or in those with sustained higher blood pressure (>135/80 mm Hg) For standard-risk pediatric patients, fasting glucose at least every 5 years; if abnormal, screen annually	For IFG, encourage weight reduction and increased physical activity. For type 2 DM, lifestyle therapy, and pharmacotherapy, if necessary, should be used to achieve near-normal HbA1C (<7%).

Abbreviations: BMI, body mass index; CIBMTR, Center for International Blood and Marrow Transplant Research; DM, diabetes mellitus; DXA, dual X-ray absorptiometry; EBMT, European Group for Blood and Marrow Transplantation; HbA1C, hemoglobin A1C; HCT, hematopoietic cell transplantation; IFG, impaired fasting glucose; LDL, low-density lipoprotein; TG, triglycerides

**Table 5**  
**Risk factors to consider when screening for components of metabolic syndrome in transplant recipients**

---

- Personal history
- Family history
- Type of transplant (allogeneic or autologous)
- TBI as part of pre-transplant conditioning
- Development of acute or chronic GVHD
- Ongoing therapy with corticosteroids
- Ongoing therapy with calcineurin inhibitors
- Ongoing therapy with sirolimus
- Presence of additional metabolic syndrome components

---

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript